ARTICLE SUMMARY:
CDRH’s small Division of Health Equity oversaw a program linking medtech firms to insurers and managed SBIR grant reviews, agency partnerships, and pediatric and women’s health programs, among other responsibilities. HHS eliminated DHE as part of its recent “reductions in force,” Market Pathways has learned.
A CDRH division that oversaw innovation, pediatric, and women’s health activities was among units eliminated by the Department of Health and Human Services’ large-scale April 1 “reduction in force” (RIF) action, Market Pathways has learned from current and former FDA staffers.
The Division of Health Equity (DHE) was not a well-known office outside of FDA, but it helped administer a diverse array of programs including outreach efforts to payors, start-ups, and sister HHS agencies, and activities to advance medtech innovation for women’s health and pediatrics.
